The overall objective of this contract is to advance the development, including U.S. Food and drug administration (FDA) approval, of atropine autoinjector for pediatric use using an improved version…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00055
- Awardee
-
Rafa Laboratories LTD UEI CKDNTKNDPMJ6
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $9,371,145
Award facts
- Contract value 64% obligated
-
- $9,371,145.00 Current, with exercised options
- $14,715,580.00 Potential, with all options
- Completion date 49% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Israel
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,670,282 | |
| Other Administrative Action | $0 | |
| Original award | $7,700,863 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $14.7 million definitive contract to Rafa Laboratories LTD for advancement of development and FDA approval of an atropine autoinjector for pediatric use on September 19, 2023. The contract uses cost-plus-fixed-fee pricing with no set-aside category.
Place of performance is Israel. The originating solicitation calls for development of an improved version of Rafa Laboratories' FDA-approved pediatric atropine autoinjector, advancing the device through regulatory pathways toward approval. Work continues through January 1, 2030. The contract ceiling value is $14.7 million. Supplemental funding was provided to revise the statement of work, add an alternate contracting officer representative, and add FAR clause changes via attachment.
Description
The overall objective of this contract is to advance the development, including U.S. Food and drug administration (FDA) approval, of atropine autoinjector for pediatric use using an improved version of rafa laboratories, LTD.s (rafas) FDA-approved SI
Quick answers
Who was awarded contract 75A50123C00055?
75A50123C00055 was awarded to Rafa Laboratories LTD by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 19, 2023.
How much is contract 75A50123C00055 worth?
The government has obligated $9,371,145 on 75A50123C00055. Its potential value, with all options, is $14,715,580.
Was contract 75A50123C00055 competed?
The extent of competition for 75A50123C00055 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award